13th Annual Land O’Lakes Conference on Drug Metabolism/Applied Pharmacokinetics
September 13-27, 2010
Devil's Head Resort
Merrimac, WI
Developed & Conducted by Extension Services in Pharmacy, School of Pharmacy, University of Wisconsin- Madison.
Registration
Your registration options are as follows:
 |
Register Online. Login in using your user account. If you don't have a user account creating one is free & easy. |
 |
Download the registration form, complete & mail to: LOL Drug Metabolism Conference |
 |
By phone at 608.262.3130 or toll-free at 877-947-4255 using a credit card for payment. |
 |
Download the registration form, complete & fax to 608.262.2431 using a credit card for payment. |
Conference Goals & Objectives
The purpose of this four-day professional development conference is to provide an educational outreach forum to discuss the current issues in selecting potential new therapeutic entities for preclinical trials and current issues in drug metabolism and preclinical pharmacology. General goals associated with this conference include:
- To provide a better understanding of the role of drug metabolism in the pharmacokinetics and pharmacodynamics of new product candidates, including biotechnology-derived drugs.
- To evaluate new techniques and shared experiences in the area of “high through-put screening” and drug discovery screenings.
- To gain insight into problems and issues encountered during the pharmaceutical industry research and drug development process and the interface between drug discovery and development.
- To discuss current regulatory issues affecting preclinical and early clinical development, both within the United States and globally.
- To identify processes for improving the identification of successful drug candidates through metabolite identification and in-vitro/in-vivo implications.
- To discuss current drug metabolism systems and their applicability in R&D activity.
- To gain insight from various perspectives on the drug-discovery process, including industry, academia, and regulatory agencies, including the Food and Drug Administration (FDA).
Last years course evaluation results.
Special Offer for Academic Institutions
Extension Services in Pharmacy at the University of Wisconsin School of Pharmacy has instituted a new policy for industrial professional development programs to encourage greater participation by faculty, graduate students and post doctoral students at academic institutions. Programs will be offered at a significantly reduced price, based on space availability. For information about any specific course please contact Dr. James E. De Muth by email.
2010 Conference Planning Committee
Robert J. Guttendorf, Ph.D., Conference Chair, Sequoia Pharmaceuticals, Inc., Gaithersburg, MD
James E. De Muth, Ph.D., Conference Director, University of Wisconsin, Madison, WI
James L. Ferrero, Ph.D., DMPK Consultant, La Jolla, CA
Randall H. Guthrie, Xcelience, LLC, Lodi, WI
David A. Hartman, Ph.D., Fulcrum Pharma Developments, Inc., Morrisville, NC
Suhasini Iyer, Ph.D., Genentech, Inc., South San Francisco, CA
Patrick Koch, Ph.D., Sepracor, Inc., Marlborough, MA
Gordon R. Loewen, Ph.D., BiogenIdec, Cambridge, MA
Mark N. Milton, Ph.D., Novartis Biologics, Cambridge, MA
Ivan Nestorov, Ph.D., BiogenIdec, Cambridge, MA
Jasminder Sahi, Ph.D., CellzDirect/Invitrogen, Ann Arbor, MI
Paul Savina, GlaxoSmithKline, Research Triangle Park, NC
James M. Schmidt, Lexicon Phamraceuticals, The Woodlands, TX
Arzu Selen, Ph.D., Center for Drug Evaluation and Research, FDA, Rockville, MD
Michael Sinz, Ph.D., Bristol Myers Squibb, Wallingford, CT
Vangala Subrahmanyam, Ph.D., Sai Advantium Pharma Limited, Hinjewadi, India
Steven Swanson, Ph.D., Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN
Larry M. Tremaine, Ph.D., Pfizer, Inc., Groton, CT
Richard L. Voorman, Ph.D., Abbott Laboratories, Abbott Park, IL
Ping Zhao, Ph.D., Office of Clinical Pharmacology. CDER, Food and Drug Administration, Silver Spring, MD
Conference Support for 2009
Speical thanks for unrestricted educational grant to help support this conference from
Charles River Laboratories |  |
NoAb BioDiscoveries Inc. |
 |
BD Biosciences |  |
Conference Travel Information
Location & Travel
The conference will be presented at Devil's Head Resort in Merrimac, Wisconsin. Merrimac is approximately 40 minutes from Madison. For those registrants flying into Madison, bus transportation will be available to and from Devil's Head Resort.
Shuttle Bus Service to and from the Dane County Regional Airport
Monday 1:30 and 4:30 PM | Friday 10:45 AM |
Sponsored by: |  |
2010 Conference Fees
Registration Fee |
$1250 |
Lodging & Meals: Single Accommodations |
$625 |
Total Amount |
$1875 |
If Payment received prior to June 21, 2010 |
-$150 |
EARLY REGISTRATION |
$1725 |
NOTE: All accommodations at Devil's Head for conference registrants will be processed through Extension Services in Pharmacy. Fees are based on a single accommodation. Additional fees will be assessed for both lodging in the event more than one person occupies a room.
Enrollment Deadlines/Limits
A check in the total amount payable to UNIVERSITY OF WISCONSIN should accompany your application to ensure that space will be held for you. Credit card payment is also acceptable. Total payment will be returned /refunded if space is not available.
In the event your registration is confirmed and at a later date you are unable to personally attend, a refund (less a $50 administrative fee) will be provided June 21; after June 21, no refunds will be made. You may fax your registration (608) 262-2431 with payment to follow no later than June 21. After June 21, space will not be held without receipt of payment.
Social Activities
In addition to the educational benefits of this program, the conference is designed to provide registrants with a relaxing environment to meet and share ideas with colleagues with similar interests and network for future collaborative effort. To this end, Devil's Head Resort offers a variety of activities including tennis, indoor and outdoor swimming pools, mountain bikes, nature trails and one of the finest golf courses in Wisconsin. Golf, at a significantly reduced rate, is available to all registrants during Tuesday and Wednesday afternoons of the conference.
For More Information
James E. De Muth, Ph.D., Conference Director
Extension Services in Pharmacy
777 Highland Avenue
Madison, WI 53705
(608) 262-3130
FAX (608) 262-2431
Send Email
2009 Program Outline (2010 Program is currently being developed)
Monday, September 14 |
|
|||
6:00pm |
Opening Reception
|
|||
7:00pm |
Dinner |
|||
Tuesday, September 15 |
First Plenary Session - Application and Development of Monoclonal Antibodies as Drugs |
|||
8:00am |
Welcome and Conference Overview
|
|||
8:15am |
Overview Presentation
|
|||
9:15am |
Assay Methodologies
|
|||
10:00am |
Break |
|||
10:30am |
PK/PD Modeling
|
|||
11:15am |
First in Human studies: The Impact of the TeGenero Incident
|
|||
12:00pm |
Lunch |
|||
|
||||
1:00pm |
Afternoon Session – Case Studies of a Monoclonal Antibody Development
|
|||
2:45pm |
Boat Tour of Upper Dells
|
|||
6:30pm | Dinner | |||
Evening Session
| ||||
8:00pm |
Disease States and Effects on the Drug Metabolizing Systems
|
|||
9:00pm |
Dessert Reception
|
|||
Wednesday, September 16 |
Second Plenary Session: Dealing with Disproportionate Metabolite Exposure
|
|||
8:00am |
Overview of the MIST Guidance and Implications for DM/PK
|
|||
9:00am |
Application of Metabolites in Drug Development
|
|||
9:50am |
Break |
|||
10:20am |
Analytical Identification of Metabolites
|
|||
11:10am |
Pharmacogenomics and Implications of the PhRMA White Paper Report
|
|||
12:00pm |
Lunch |
|||
|
1:00pm |
Afternoon Session: Relevant White Paper Reports
Transporters
|
|||
1:30 |
Time-Dependent Enzyme Inhibition
| |||
2:00 |
Enzyme Induction
| |||
2:30 |
Panel Discussion
| |||
5:00pm |
Poster Session with Authors |
|||
|
5:00pm |
Wine and Cheese Reception
| |||
6:30pm |
Dinner |
|||
8:00pm |
Evening – Round Table Discussions 1. Interspecies Scaling for Large Protein Molecules
2. Metabolite Scale-up, Isolation, and Identification
3. Successes and failures in accelerating compounds to FIH trials
4. How are we dealing with Reactive Metabolites?
5. Role of DMPK Data on Candidate Progression from Nomination to Regulatory Approval
|
|||
Thursday, September 17 |
Third Plenary Session: Integrated Models
|
|||
8:00am |
Overview of Integrated Models for Drug Development
|
|||
8:50am |
Increasing Accuracy of Drug Interaction Predictions through Modeling and Simulations: Applications in Discovery and Development
|
|||
9:30am |
GastroPlus
|
|||
10:10am |
Break |
|||
10:30am |
An Integrated Model to Predict in vivo Metabolic Interactions that Involve CYP Inactivation,Induction and Inhibition
|
|||
11:10pm |
FDA Perspective
|
|||
12:00pm | Lunch | |||
1:00pm |
Afternoon Session: Emerging Novel Drug Delivery Systems
|
|||
1:00pm |
Nanotechnology Applications for Drug Delivery
|
|||
2:45pm |
Tour to Wollershiem Winery
|
|||
6:30pm |
Dinner |
|||
Evening Presentations
|
||||
8:00pm |
Big Battles and Big Pharma: The Drug Industry Comes of Age During the American Civil War
|
|||
9:00pm |
Traditional Wisconsin Cheese Boxes
|
|||
Friday, September 18 |
Fourth Plenary Session: Pediatric Guidances
|
|||
8:30am |
EMEA Perspective on Pediatrics in Drug Development
|
|||
9:20am |
FDA Perspective on Pediatrics in Drug Development
|
|||
10:10am |
Panel Discussion
|
|||
10:30am |
Adjournment |
|||
|
